Company Overview and News

7
TGTX / TG Therapeutics, Inc. null

2018-09-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A
TGTX

7
TGTX / TG Therapeutics, Inc. null

2018-08-22 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y [email protected] [email protected],C
TGTX

8
TGTX / TG Therapeutics, Inc. null

2018-08-22 sec.gov - 1
 
TGTX

9
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?

2018-08-20 zacks - 2
Investors in TG Therapeutics, Inc. (TGTX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $18 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
TGTX

10
TG Therapeutics Is Worth A Look Before Phase 3 Combination Cancer Data

2018-08-18 seekingalpha - 3
TG Therapeutics expects to report phase 3 cancer data next month from its study using TG-1101 (ublituximab) and TGR-1202 (umbralisib) to treat patients with first-line r/r chronic lymphocytic leukemia.
TGTX

14
Checkpoint Therapeutics: Potential For A Near-Term Run Up

2018-08-14 seekingalpha - 4
Shares have fallen by around 60% since the company´s common stock made its way onto the Nasdaq.
AZN TGTX AZN NHLD CKPT FBIO CLVS

8
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results

2018-08-07 globenewswire - 1
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2018 and recent company developments.
TGTX

7
TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis

2018-08-07 globenewswire
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the safety and efficacy of ublituximab (TG-1101), the Company’s glycoengineered anti-CD20 monoclonal antibody, as compared to teriflunomide, in patients with relapsing forms of Multiple Sclerosis (RMS).
TGTX

8
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2018 Financial Results and Business Update

2018-08-06 globenewswire - 1
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Tuesday, August 7, 2018 at 4:30pm ET to discuss results for the second quarter of 2018 and provide a business outlook for the remainder of the year. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call.
TGTX

24
Fortress Biotech: Highly Complex, Greatly Undervalued

2018-07-17 seekingalpha - 1
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.
MBIO FBIOP TGTX AAV TEVA CKPT TBI CNLM TEVVF FBIO OACQ ATXI OACQW TEVJF OACQU OACQR NHLD

64
Oncolix, Inc. Forms Scientific and Clinical Advisory Board and Appoints First Member

2018-07-17 accesswire - 1
HOUSTON, TX / ACCESSWIRE / July 17, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has appointed Robert Niecestro, PhD as its first member of its Regulatory Strategy, Scientific and Clinical Advisory Board.
ATXI AXSM TGTX KERX CKPT CTXR

7
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D/A (Activist Investment)

2018-07-11 sec.gov
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

7
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D/A (Activist Investment)

2018-07-11 sec.gov
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

TGTX : TG Therapeutics Stock Analysis and Research Report

2017-11-09 - Asif

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 88322Q108